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Abstract Gender-based differences found in cardiovascular 
diseases raise the possibility that estrogen may have direct 
effects on cardiac tissue. Therefore we investigated whether 
cardiac myocytes and fibroblasts express functional estrogen 
receptors. Immunofluorescence demonstrated estrogen receptor 
protein expression in both female and male rat cardiac myocytes 
and fibroblasts. Nuclear translocation of the estrogen receptor 
protein was observed after stimulation of cardiomyocytes with 
17ß-estradiol (E2). Cells transfected with an estrogen-responsive 
reporter plasmid showed that treatment with E2 induced a 
significant increase in reporter activity. Furthermore, E2 induced 
a significant increase in expression of the estrogen receptors a 
and ß, progesterone receptor and connexin 43 in cardiac 
myocytes. Cardiac myocytes and fibroblasts contain functional 
estrogen receptors and estrogen regulates expression of specific 
cardiac genes. These data suggest that gender-based differences 
in cardiac diseases may in part be due to direct effects of estrogen 
on the heart. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
There are significant gender-based differences in the inci-
dence of a wide variety of cardiovascular diseases, including 
coronary artery disease (CAD) [1,2], sudden death [3], and 
hypertension [4-7]. Although attention has recently focused 
on gender-specific characteristics of CAD, the importance of 
gender in the development of hypertensive heart disease is less 
well understood. Women have a lower prevalence of left ven-
tricular hypertrophy (LVH) than men [4,7]. For many years, 
this was attributed largely to differences between men and 
women in body size and risk factor profiles (e.g. hyperten-
sion). Analysis of the Framingham Heart Study data, how-
ever, showed that left ventricular mass is significantly greater 
in men than in women even after indexing for body surface 
area [5]. Furthermore, even amongst patients with known hy-
pertension, male gender correlates strongly with the develop-
ment of LVH [6]. 
The results of several recent studies demonstrating clinically 
relevant gender-based differences in the pathophysiology of 
hypertensive heart disease have raised new questions regard-
ing the mechanisms responsible for the observed differences. 
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For example, the CARDIA study demonstrated that the high-
er prevalence of LVH in men remains even after correction for 
a large number of risk factors, and further demonstrated that 
these differences in left ventricular size begin early in life (i.e. 
prior to menopause [7]). Taken together these studies suggest 
intrinsic factors may modulate the response to pathophysio-
logic factors that induce LVH. 
We, and others, have hypothesized that the steroid sex 
hormone estrogen contributes to the reduced propensity 
for the development of LVH in females. This hypothesis is 
supported by data derived from several different animal 
models. Rat models of pulmonary hypertension demonstrate 
that ovariectomy potentiates the induction of right ventricular 
hypertrophy while estrogen replacement attenuates this re-
sponse [8]. Furthermore, estrogen treatment inhibits the devel-
opment of LVH in sinoaortic denervated rats [9]. Thus, these 
studies suggest that circulating estrogens contribute to the 
observed gender-based differences in the development of 
LVH. 
Although the specific mechanisms by which estrogen exerts 
its cardioprotective effects are unknown, two general path-
ways are likely: (1) effects of estrogen on systemic factors; 
and (2) direct effects of estrogen on cardiac cells. Estrogens 
are known to alter several systemic factors that may play a 
role in the development of hypertensive heart disease. For 
example, estrogen replacement therapy is associated with re-
duced circulating levels of both angiotensin converting en-
zyme activity [10] and insulin [11]. We hypothesized that in 
addition to these systemic effects of estrogen, direct effects of 
estrogen on cardiac tissue might also contribute to the ob-
served gender-based differences in cardiac diseases. 
Nearly all of the known biological effects of estrogen are 
mediated by the estrogen receptor, an intracellular protein 
that regulates gene expression in an estrogen-dependent fash-
ion [12,13]. Though previous studies demonstrated binding of 
radiolabeled estrogen to cardiac tissue [14,15], the presence 
and functional integrity of estrogen receptors in the heart 
have not yet been established. Therefore, we sought to deter-
mine whether cardiac myocytes and/or fibroblasts express 
functional estrogen receptors. In the present study, we dem-
onstrate, for the first time, that both cardiomyocytes and car-
diac fibroblasts contain estrogen receptor protein and that the 
receptor is capable of estrogen-mediated gene activation. 
These data identify the heart as a target organ for direct 
effects of estrogen on the cardiovascular system. 
2. Materials and methods 
All chemicals were obtained from Merck, Darmstadt, Germany if 
not otherwise specified. 
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2.1. Cell culture techniques 
rats Wistar-Kyoto strain rats, 1-2 days old, were separated by 
gender and hearts were isolated and digested with 10 ml of Spinner 
solution (116 mM NaCl, 5.3 mM KC1, 8 mM NaH2P04 , 22.6 mM 
NaHC03 , 10 mM HEPES, 5 mM D-Glucose, pH 7.4) containing 0.1% 
collagenase (Cytogen; Berlin, Germany) for 10 min at 37°C in eight 
consecutive steps (modified after [16]). After each digestion, the me-
dium containing the suspended cardiac cells was removed and an 
equal volume of Spinner/collagenase solution was added. The cardiac 
cell suspension was mixed with an equal volume of Ham's FIO (Gibco 
BRL; Eggenstein, Germany) supplemented with 10% horse serum 
(HS; Biochrom; Berlin, Germany), 10% estrogen-free fetal calf serum 
(FCS; c.c.pro; Hamburg, Germany) and 25 μg/ml gentamicin (Gibco 
BRL; Eggenstein, Germany) and stored at 4°C. Heart tissue was 
digested until the cells were completely suspended. Suspensions were 
centrifuged at 400 Xg for 5 min and the cell pellets were resuspended 
in 20 ml of Ham's FIO supplemented with 10% HS and 10% FCS and 
plated on culture dishes. After 75 min the medium which contained 
the cardiomyocyte fraction of the digested tissue was removed. The 
adherent fraction of the plated cells consisted of cardiac fibroblasts. 
The dishes were gently rinsed three times to remove remaining cardi-
omyocytes. Cardiomyocytes were counted in a Fuchs-Rosenthal 
chamber and seeded on culture dishes at a density of 2 x l 0 4 cells/ 
cm2 for immunofluorescent staining and 3 X 104 cells/cm2 for trans-
fection. The culture medium for cardiac fibroblasts was exchanged for 
DMEM (Gibco BRL; Eggenstein, Germany) supplemented with 20% 
estrogen-free FCS and 25 μg/ml gentamicin. The cardiomyocyte cul-
ture contained 90-95% myocytes, as assessed by immunofluorescence 
staining with an antibody against troponin-t (CP05, Dianova; Ham-
burg, Germany; data not shown). Purity of cardiac fibroblast culture 
was assessed by repeated differential plating and microscopic evalua-
tion. 
2.2. Immunoblotting 
2 x 106 neonatal cardiomyocytes and cardiofibroblasts were lysed in 
2 ml of the following buffer: 50 mM NaCl, 20 mM Tris (pH 7.4), 50 
mM NaF, 50 mM EDTA, 20 mM sodium pyrophosphate (№4Рг07), 
1 mM sodium orthovanadate (Na3V04), 1% Triton X-100, 1 mM 
PMSF, 0.6 mg/ml leupeptin and 10 μg/ml aprotinin. Total cell lysates 
(50 ц^1апе) were analyzed by SDS-PAGE in a 7.5% gel and trans-
ferred to a nitrocellulose membrane. Protein content was measured 
with a standard Bradford assay. Immunoblotting was performed with 
either a monoclonal anti-estrogen receptor a antibody (SRA 1000, 
1:1000 dilution, Biomol; Hamburg, Germany) or anti-estrogen recep-
tor ß antibody (1:500, Dianova; Hamburg, Germany), anti-progester-
one receptor antibody (SRA 1100, 1:1000 dilution, Biomol; Ham-
burg, Germany) or anti-connexin 43 antibody (C13720 Transduction 
Laboratories 1:250, Dianova, Hamburg, Germany) followed by de-
tection with the enhanced chemiluminescence technique (ECL, Amer-
sham). Densitometric analysis of protein induction was performed on 
an Epson GT 8000-scanner with the analysis software ScanPak (Bio-
metra; Göttingen, Germany). 
2.3. Immunofluorescent staining of the estrogen receptor 
Neonatal cardiac myocytes were grown on uncoated glass coverslips 
for immunofluorescent staining. Cellular staining was performed as 
previously described with minor modifications [17]. Cells were fixed 
with 2% paraformaldehyde and phosphate-buffered saline. Immuno-
fluorescent studies of the estrogen receptor were performed with a 
1:20 dilution of a polyclonal rabbit antibody (kind gift of K. Yoshi-
naga, NIH, Bethesda, MD) against a synthetic peptide identical to an 
18 amino acid fragment from the hinge region of the rat estrogen 
receptor [18]. Progesterone receptor was detected with a monoclonal 
mouse antibody against a synthetic peptide identical to amino acids 
523-536 of the chicken progesterone receptor (SRA 1100, 1:500 dilu-
tion, Biomol; Hamburg Germany). A goat anti-rabbit IgG conjugated 
DTAF was used as a secondary antibody (Dianova; Hamburg; Ger-
many). Studies in which the primary antibody was omitted served as 
negative controls. A Zeiss MC405 microscope equipped with a Zeiss 
Plan-Apochromat 63/1.4 was used for conventional fluorescence mi-
croscopy. The confocal imaging system consisted of a Zeiss Axiophot 
fluorescence microscope, a BioRad MRC-600 confocal scanner and a 
Silicon Graphics Workstation. The images were recorded using a 
Zeiss Neofluar 63/1.3 objective. The system was equipped with an 
argon/krypton mixed gas laser. Image processing was done on a Sil-
Fig. 1. Rat neonatal cardiac myocytes express estrogen receptor pro-
tein. Unstimulated (upper) and 17ß-estradiol-stimulated (lower) car-
diac myocytes grown on glass coverslips were immunostained with 
an anti-estrogen receptor primary antibody and a DTAF-conjugated 
secondary antibody. In the absence of estrogen, confocal laser scan 
microscopy revealed a mixed cytoplasmic and nuclear distribution 
of the estrogen receptor. After 17ß-estradiol treatment the estrogen 
receptor protein was found predominantly in the nucleus. Magnifi-
cation 630 X. 
icon Graphics Workstation using 'Imaris' (Bitplane AG; Zürich, Swit-
zerland), a 3D multi-channel image processing software specialized for 
confocal microscopic images [19-21]. Cells were studied following 24 
h incubation in the absence or presence of 10~6 M 17ß-estradiol. 
2.4. Transfection assay 
Neonatal rat cardiac myocytes and fibroblasts were seeded at a 
density of ЗхЮ 4 cells/cm2 for transfection. Cells were transfected 
using a liposome-conjugated transfection technique according to the 
manufacturer's instructions (DOTAP; Boehringer-Mannheim, Ger-
many). Cells were transfected with a constitutively expressed ß-galac-
tosidase plasmid (see below) and either ERE-LUC (containing three 
copies of the vitellogenin estrogen-responsive element driving expres-
sion of the luciferase gene (kind gift of С Glass)) or TK-LUC (the 
same plasmid as ERE-LUC but lacking the estrogen responsive ele-
ments; also the gift of С Glass). After 24 h, the transfection medium 
was removed and cardiomyocytes were maintained in phenol red-free 
Ham's FIO with angiotensin II (100 nM; Sigma Chemicals; St. Louis, 
MO), isoproterenol (100 μΜ; Sigma Chemicals; St. Louis, MO), L-
phenylephrine (100 μΜ; Sigma Chemicals; St. Louis, MO), insulin 
(10 μg/pill; Serva; Heidelberg, Germany), transferrin (10 μg/ml; Ser-
va; Heidelberg, Germany), ascorbic acid (100 μΜ; Sigma Chemicals; 
St. Louis, MO), vitamin B12 (1.5 μΜ; Serva; Heidelberg, Germany), 
sodium selenite (20 nM) and BrdU (100 μΜ; Sigma Chemicals; St. 
Louis, MO) in the absence or presence of 17ß-estradiol (Sigma Chem-
icals; St. Louis, MO) and/or ICI 182780, a pure estrogen antagonist 
(kind gift of Dr. A. Wakeling, Zeneca Pharmaceuticals, Cheshire, 
UK). Cardiac fibroblasts were maintained in DMEM plus 1% estro-
gen-free FCS. Phenol red-free medium was used throughout all ex-
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periments as phenol red is known to act as a weak estrogen [22], An 
equal volume of vehicle alone (0.1% ethanol) was added to control 
cells. Following 24 h of incubation in the experimental conditions, 
cells were harvested and luciferase activity was determined on a lu-
minometer (C-Gem, Optocom 1) as described [23,24]. In a subset of 
each transfection series, cells were transfected with pL7RH- Gal (SV-
40 promoter including a nuclear localization signal driving the ß-gal-
actosidase cDNA). Transfection efficiency was determined by staining 
of the transfected cells. Cells were washed with phosphate buffered 
saline and then fixed in 0.5% glutaraldehyde for 10 min followed 
by three more washes. They were then incubated overnight at 37°C 
in a staining solution containing 15 mM K3Fe(CN)6, 15 mM 
K2Fe(CN)6-3H20, 0.15 mM MgCl2, 1% DMSO and 1 mg/ml X-
Gal. Nuclei of cells stained for ß-galactosidase activity were counted 
and the results of each luciferase determination were normalized for 
the transfection efficiency. 
2.5. Statistical analysis 
All reported values are mean ± S.E.M. Statistical comparisons were 
made by Student's /-test. Statistical significance was assumed if a null 
hypothesis could be rejected at the P<0 .05 level. 
3. Results 
To determine estrogen receptor expression and the intra-
cellular location of the estrogen receptor, immunofluorescent 
staining was carried out. In the absence of 17ß-estradiol, es-
trogen receptor was detected in both the cytosolic and nuclear 
Fig. 2. Rat neonatal cardiac fibroblasts express estrogen receptor 
protein. Unstimulated (upper) and 17ß-estradiol-stimulated (lower) 
cardiac fibroblasts grown on glass coverslips were immunostained 
with an anti-estrogen receptor primary antibody and a DTAF-con-
jugated secondary antibody. As with cardiomyocytes, in the absence 
of estrogen, the estrogen receptor demonstrated a mixed cytoplasmic 
and nuclear distribution. After 17ß-estradiol treatment the estrogen 
receptor protein was found predominantly in the nucleus. Magnifi-
cation 630 X. 
Fig. 3. Rat neonatal cardiac myocytes and fibroblasts contain tran-
scriptionally competent estrogen receptor. Rat neonatal cardiac my-
ocytes (upper panel) or cardiac fibroblasts (lower panel) were trans-
fected with a reporter plasmid (ERE-LUQ in which an estrogen-
responsive element drives expression of the firefly luciferase gene. 
Cells were grown in the absence or presence of 17ß-estradiol (E2) or 
the anti-estrogen ICI 182780 (10~8 M) and harvested after 24 h. 
Bars represent the mean luciferase activity with S.E.M. Luciferase 
activity is shown relative to control cells that were not exposed to 
hormones. 
compartments of cardiac myocytes and fibroblasts (Figs. 1 
and 2, respectively). Incubation of the cells in 10~6 M 17ß-
estradiol for 24 h induced nuclear translocation of the recep-
tor protein. In control experiments in which the primary anti-
body was omitted, no staining was detected (data not shown). 
Because of the complex regulation of steroid hormone recep-
tor activation [25,26], the presence of estrogen receptor pro-
tein does not establish unequivocally the ability of these cells 
to respond directly to estrogen exposure. Therefore, to dem-
onstrate the functional competence of the receptor, transient 
transfection experiments were carried out using a well charac-
terized estrogen-responsive reporter plasmid, ERE-LUC [27]. 
Unpassaged rat cardiomyocytes transfected with ERE-LUC 
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showed dose-dependent transactivation of the reporter con-
struct after incubation with 17ß-estradiol (Fig. 3). Maximal 
activation of the reporter (male: 13± 1.68-fold, female 
49.1 ± 1.10-fold; « = 9, P<0.01) occurred at an estrogen con-
centration of 10~8 M. Similarly, cardiac fibroblasts trans-
fected with ERE-LUC also showed dose dependent activation 
of the reporter (male: 24.47±0.23-fold, female 60.55 ± 1.08-
fold; n = 9, P<0.01) . In contrast, the control plasmid lacking 
the estrogen receptor-responsive element (TK-Lf/C) revealed 
no evidence of hormonal induction in either cell type (data 
not shown). The specificity of the estrogen-induced activation 
of ERE-LUC was demonstrated further by the inhibition of 
activation observed when the specific estrogen antagonist ICI 
182780 was added to the experimental media (Fig. 3). Taken 
together, these data demonstrate that the estrogen receptor in 
cardiomyocytes and cardiac fibroblasts is functionally intact. 
Western blot analysis with specific monoclonal estrogen re-
ceptor antibodies directed against the estrogen receptor a 
and estrogen receptor ß isoform detected the 66/60 kDa estro-
gen receptor protein in lysates derived from neonatal cardio-
myocytes (Fig. 4A,B). In addition, we could also demonstrate 
expression of the estrogen receptor in immunoblot analysis 
derived from male and female cardiac fibroblasts (data not 
shown). Although the level of protein expression in both cell 
types was low in the absence of 17ß-estradiol, incubation in 
10~9 M 17ß-estradiol for 24 h led to a marked increase in the 
abundance of estrogen receptor protein. Immunostaining with 
a different primary antibody (NIH 715) showed the same 
result and control experiments in which the primary antibody 
was omitted were negative (data not shown). Thus, these stud-
ies confirm the immunofluorescent analysis demonstrating es-
trogen receptor protein in cardiac cells. 
In non-cardiac cells, estrogen-mediated regulation of pro-
gesterone receptor gene expression is well known [28]. To 
determine whether estrogen, besides its potential to upregulate 
the expression of the estrogen receptor, regulates the expres-
sion of endogenous cardiac genes, we assessed the level of 
Fig. 4. A: Estrogen induces increased estrogen receptor a protein 
expression. Total cellular lysates of male and female cardiac myo-
cytes grown in the absence (a) or presence of 10~9 M 17ß-estradiol 
were subjected to SDS-PAGE, immunoblotted with an anti-estrogen 
receptor antibody, and developed with a chemiluminescence tech-
nique. E2 induced a 6.4-fold increase (b: male) and a 14.8-fold in-
crease (c: female) in expression of the estrogen receptor a in cardiac 
myocytes. The 66 kDa estrogen receptor (ER) protein migrates as 
indicated by the arrow. Coincubation with the anti-estrogen ICI 
182780 inhibited receptor induction by estrogen (d). Lysate from 
adult rat ovary served as a positive control (e). One of three similar 
studies is shown. B: Estrogen induces increased estrogen receptor ß 
protein expression. Total cellular lysates of male and female cardiac 
myocytes grown in the absence (a) or presence of 10~9 M 17ß-estra-
diol were subjected to SDS-PAGE, immunoblotted with an anti-es-
trogen receptor antibody, and developed with a chemiluminescence 
technique. E2 induced a significant increase (b: male/c: female) in 
expression of the estrogen receptor ß in cardiac myocytes, respec-
tively. The 60 kDa estrogen receptor (ER) protein migrates as indi-
cated by the arrow. One of three similar studies is shown. 
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Fig. 5. Estrogen induces increased expression of the endogenous 
progesterone receptor gene in rat neonatal cardiomyocytes. Total 
cellular lysates of female (a,b,c) and male (d,e) rat neonatal cardio-
myocytes grown in the absence or presence of 10-9 M 17ß-estradiol 
were separated by SDS-PAGE, immunoblotted with an anti-proges-
terone receptor antibody and developed with chemiluminescence 
techniques. The 84 kDa progesterone receptor (PR) could be de-
tected in unstimulated cells (a,d). Estrogen exposure increased pro-
gesterone receptor protein content (b: female, 17.5-fold; d: male, 
16-fold). Coincubation with the anti-estrogen ICI 182780 inhibited 
the induction (c). Lysate from adult rat ovary served as a positive 
control (f). One of three similar studies is shown. 
progesterone receptor protein in male and female cardiomyo-
cytes in the absence and presence of 17ß-estradiol. Immuno-
blot analysis of lysates from rat neonatal cardiomyocytes 
grown in the presence of 10~9 M 17ß-estradiol identifies a 
band with a molecular weight of 84 kDa (Fig. 5), correspond-
ing to the expected size of the A isoform of the rat progester-
one receptor [29]. In the absence of 17ß-estradiol only a weak 
signal was detected. Quantification of the intensity of the sig-
nal representing the progesterone receptor in three separate 
experiments demonstrated that estrogen exposure resulted in 
a increase in progesterone receptor protein expression (male: 
12.6, female: 13.4; Fig. 5). Furthermore, immunoblot analysis 
of lysates from cardiac myocytes demonstrated a band of 43 
kDa, which corresponds to the size of the gap junction protein 
connexin 43 [30]. Connexin 43 expression was upregulated 
after incubation with 10~9 M E2 (male: 6.2-fold, female: 
24.8-fold). Again, in the absence of 17ß-estradiol only a 
weak signal was detected (Fig. 6). In addition, we could 
also demonstrate expression of the progesterone receptor 
and connexin 43 in immunoblot analysis derived from neo-
natal male and female cardiac fibroblasts (data not shown). 
Quantification of the intensity of the signal representing con-
nexin 43 expression in three separate experiments demon-
strated that estrogen exposure resulted in the protein expres-
sion mentioned before (w = 3; P < 0.05). These data 
demonstrate that estrogen can modulate expression of endog-
enous cardiac genes and reveals gender-based differences in 
the activation of those genes. 
4. Discussion 
Although several clinical studies have demonstrated that 
women have a reduced incidence of LVH when compared 
to men, the mechanism(s) responsible for these observations 
is unclear. A large body of experimental data derived from 
animal studies implicates estrogen in contributing to this effect 
[9,31-33]. As noted above, estrogen deficiency potentiates, and 
estrogen replacement attenuates the development of both right 
and left ventricular hypertrophy in rat models [8,9,34]. The 
contractile function of hearts taken from ovariectomized fe-
male rats is reduced compared with normals, and this deficit is 
reversed in mice treated with estrogen replacement [35]. These 
effects on cardiac contractility are mirrored by estrogen-medi-
ated changes in expression of contractile proteins such as my-
osin heavy chain [32,36]. Estrogen treatment prevents the de-
crease in the ratio of VI to V3 myosin isoforms in 
hypertensive rats [36]. Additional mechanisms, suggested by 
in vivo animal models, by which estrogen may regulate the 
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Fig. 6. Estrogen induces increased expression of the connexin 43 
gene in rat neonatal cardiomyocytes. Total cellular lysates of male 
(a,b,c) and female (d,e,f) rat neonatal cardiomyocytes grown in the 
absence or presence of 10-9 M 17ß-estradiol were separated by 
SDS-PAGE, immunoblotted with an anti-connexin 43 antibody and 
developed with chemiluminescence techniques. The 43 kDa connexin 
43 (CNX 43) expression was difficult to detect in unstimulated cells 
(a), estrogen exposure increased connexin 43 protein content in my-
ocytes (lane d: male: 6.2-fold; lane e: female: 24.8-fold). Coincuba-
tion with the anti-estrogen ICI 182780 inhibited the induction (c,f). 
Lysate from adult rat brain served as a positive control (g). One of 
three similar studies is shown. 
contractile function and metabolic state of the myocardium, 
include: increasing glucose uptake [37,38] and augmenting 
expression of nitric oxide synthase [39]. These studies demon-
strate clearly that estrogen plays a role in modulating the 
cardiac phenotype. Traditionally, effects of estrogen on cardi-
ovascular diseases have been attributed to the systemic effects 
of estrogens. For example, until recently the anti-atherogenic 
effects of estrogens were largely attributed to the beneficial 
effects of estrogen on lipid metabolism. More recently atten-
tion has shifted to include investigation of direct effects of 
estrogen on the vascular wall and the potential contribution 
of this additional pathway to the atheroprotective effects of 
estrogen [40]. For example, vascular smooth muscle cells are 
now known to express estrogen receptors [24,41,42], which are 
functionally intact. In addition, estrogen has been shown to 
inhibit the response to vascular injury in the mouse carotid 
artery, even without alterations in systemic lipids [43]. These 
data suggest that vascular tissue is a target organ for direct 
effects of estrogen. We hypothesized, similarly, that the heart 
may also be a target organ for estrogen action and therefore 
sought to determine whether cardiac cells express estrogen 
receptors. In the present study we demonstrate expression of 
functionally intact estrogen receptors in both cardiac myo-
cytes and fibroblasts. 
Previous attempts to demonstrate estrogen receptors in car-
diac tissue have been confined to demonstration of uptake 
into cardiac cells of radiolabeled estrogen following intrave-
nous administration [14,15,44]. Although these reports clearly 
demonstrated specific estrogen binding to heart tissue, they 
did not identify the estrogen receptor specifically as responsi-
ble for the observed binding activity, nor did they demon-
strate any biological effects resulting from estrogen binding. 
In the present study, we applied both immunoblotting and 
immunofluorescent staining to demonstrate that cardiac cells 
express estrogen receptor protein. The immunoblot experi-
ments demonstrate the presence of estrogen receptor protein 
of the expected molecular weight [45]. The immunofluorescent 
staining confirmed the presence of estrogen receptor protein, 
and further demonstrated that the intracellular distribution of 
the protein is altered by estrogen exposure, a behavior char-
acteristic of estrogen receptors in other tissues [46]. 
As with other nuclear receptors, transcriptional activation 
of the estrogen receptor is a complex process that requires the 
functional integrity of both the receptor itself and of a num-
ber of other associated proteins [25,26]. A number of mutant 
estrogen receptors in breast cancer tissues are detectable by 
immunologic methods, but are known to be transcriptionally 
silent [47]. In addition, human vascular smooth muscle cells 
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express an estrogen receptor isoform that is also detected by 
anti-estrogen receptor antibodies, but which is not capable of 
mediating alterations in gene expression [48]. Thus, demon-
stration of the presence of estrogen receptor protein in heart 
tissue is not sufficient to suggest a functional role for the 
protein. We therefore also sought to determine whether the 
estrogen receptor in cardiac myocytes and fibroblasts is capa-
ble of transcriptional transactivation and found it capable of 
high level transactivation of a classical estrogen responsive 
element in transient transfection experiments with cardiac 
cells. The specificity of this activation is demonstrated both 
by the lack of activation of the backbone vector (which does 
not contain the estrogen-responsive elements) and by inhibi-
tion of the response by the receptor antagonist ICI 182780. 
The activation observed in these experiments is similar but 
somewhat more robust than that found in other non-repro-
ductive cells such as vascular smooth muscle cells [24]. 
Although the transient transfection experiments demon-
strate estrogen-mediated activation of an exogenous gene, a 
convincing demonstration of the estrogen-responsive nature of 
cardiac cells should include the demonstration of estrogen-
regulated expression of endogenous genes. We chose to inves-
tigate estrogen effects on three genes known to respond to E2 
in non-cardiac cells: estrogen receptor, the progesterone re-
ceptor and the gap junction protein connexin 43 expression. 
Estrogen exposure markedly stimulated estrogen receptor, 
progesterone receptor and connexin 43 expression in both 
cardiac myocytes and fibroblasts, confirming the ability of 
these cells to respond directly to estrogen. Although the phys-
iologic significance of progesterone receptors in the heart is 
unknown, the addition of progesterone to estrogen treatment 
in ovariectomized mice has been shown to increase the density 
of both muscarinic and ß-adrenergic receptors [33]. In addi-
tion, we show that connexin 43 expression in neonatal cardiac 
myocytes and fibroblasts is upregulated after estrogen incuba-
tion. These observations extend our knowledge about connex-
in 43 expression in adult heart, which revealed no inducibility 
by estrogen in contrast to adult reproductive tissue which was 
shown to be estrogen sensitive [39]. In the light of recent 
observations that suggest that E2 influences coupling and un-
coupling of cardiac myocytes [48], the modulation of this gap 
junction protein by estrogen may well be of physiologic im-
portance in a large array of cardiac diseases. Interestingly, the 
inducibility of the endogenous genes revealed significant gen-
der-based differences, which leads to the suggestion that 
mechanisms other than steroid binding may play a role in 
these processes. In this context, recent studies have demon-
strated the presence of a novel variant of the estrogen receptor 
[49-51] called ER ß. This novel estrogen receptor (ER ß) may 
also play a role in the complex regulation of estrogenic effects 
in cardiovascular disease as its presence, which was shown in 
this study, suggests [52]. 
In summary, we have shown that rat neonatal cardiomyo-
cytes express functional estrogen receptors, and further, that 
estrogen exposure modulates gene expression in these cells 
and these findings support the hypothesis that the heart is a 
target organ for estrogen action. 
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